Dr Reddy's Gains on Wegovy Plans

  Published 8 months ago

Dr Reddy’s rises 2.4% on plans to launch generic Wegovy in 87 nations; analysts boost earnings forecasts on growth outlook.

  • Targets early Semaglutide launch in Canada, global rollout before March 2026 patent expiry; low competition expected.
  • Jefferies, Goldman hike FY26–28 EPS forecasts; also sees growth from Abatacept IV launch in 2027.
  • Q1 profit slightly misses on U.S. pricing pressure; stock still down ~10% YTD despite 11.4% revenue growth.

You might like these

Volvo Cars Announces 3,000 Job Cuts

Supreme Wins Rs 54 Cr BPCL Deal

Delhivery Opens Lucknow Mega Hub

HFCL Board Approves ₹700 Cr Fundraise

ACME Solar Secures 3.1 GWh Battery Storage Order

NHAI Unveils 'Asset Monetization Strategy' to Boost Road Infra PPPs

India's Rural Consumption Drives Economic Growth

News that matters the most ⚡